MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS

MeiraGTx, a New York and UK based gene therapy company, announced that it has been awarded a grant from Target ALS, a privately funded foundation bringing together a consortia of academic and biotech/pharmaceutical researchers.

Sanofi and Regeneron Announce First Approval of KevzaraTM for the Treatment of Moderately

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody.

Envisia therapeutics releases interim Env515 phase 2 data results

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial...

Cell based therapy and FDA review: Partnering for success at your pre-IND meeting

Regenerative and cell-based therapies have only recently begun to deliver on the promise they have portended for years, creating opportunities to positively impact patient outcomes and professional success.

Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m

University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford...

Intarcia Announces FDA Filing Acceptance of NDA for ITCA 650 for the Treatment of Type 2 Diabetes

Intarcia Therapeutics, Inc. announced that the U.S. FDA has accepted for active review its NDA for ITCA 650, an investigational therapy for the treatment of type 2 diabetes (T2D).

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com